CULLINAN THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
CULLINAN THERAPEUTICS, INC. (CGEM) reported Increase (Decrease) in Accounts Payable of $2.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.22M.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.67M, a 3.08% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$879.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$739.00K, a 231.96% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$839.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$812.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was -$167.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$509.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.88M 10-Q · filed 2026-08-06 | $2.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.67M 10-Q · filed 2026-05-07 | $788.00K derived: sum of 2 quarters · filed 2026-05-07 | $49.00K derived: sum of 3 quarters · filed 2026-05-07 | -$892.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.62M derived: sum of 2 quarters · filed 2026-03-10 | -$2.56M derived: sum of 3 quarters · filed 2026-08-06 | -$839.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$739.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.68M derived: sum of 2 quarters · filed 2026-08-06 | $40.00K 10-Q · filed 2025-11-06 | -$394.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$941.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $779.00K 10-Q · filed 2026-08-06 | $345.00K derived: sum of 3 quarters · filed 2026-08-06 | $905.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.72M 10-Q · filed 2026-05-07 | $1.29M derived: sum of 2 quarters · filed 2026-05-07 | $1.85M derived: sum of 3 quarters · filed 2026-05-07 | -$306.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $126.00K derived: sum of 2 quarters · filed 2026-03-10 | -$2.03M derived: sum of 3 quarters · filed 2026-03-10 | -$812.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $560.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.59M derived: sum of 2 quarters · filed 2025-11-06 | -$378.00K 10-Q · filed 2025-11-06 | $1.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$938.00K 10-Q · filed 2025-08-07 | $604.00K derived: sum of 3 quarters · filed 2025-08-07 | -$936.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.21M 10-Q · filed 2025-05-08 | $2.76M derived: sum of 2 quarters · filed 2025-05-08 | $1.22M derived: sum of 3 quarters · filed 2025-05-08 | $1.68M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.00K derived: sum of 2 quarters · filed 2025-02-27 | $463.00K derived: sum of 3 quarters · filed 2025-02-27 | -$167.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.08M derived: sum of 2 quarters · filed 2024-11-07 | -$1.71M 10-Q · filed 2024-11-07 | -$564.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$169.00K 10-Q · filed 2024-08-08 | $976.00K derived: sum of 3 quarters · filed 2024-08-08 | -$608.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$630.00K 10-Q · filed 2024-05-15 | $515.00K derived: sum of 2 quarters · filed 2024-05-15 | -$1.07M derived: sum of 3 quarters · filed 2024-05-15 | -$4.28M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$439.00K derived: sum of 2 quarters · filed 2024-03-14 | -$3.65M derived: sum of 3 quarters · filed 2024-03-14 | -$509.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$4.79M derived: sum of 2 quarters · filed 2023-11-08 | -$1.65M 10-Q · filed 2023-11-08 | -$509.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$70.00K 10-Q · filed 2023-08-10 | $1.07M derived: sum of 3 quarters · filed 2023-08-10 | $1.59M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.14M 10-Q · filed 2023-05-11 | $4.28M derived: sum of 2 quarters · filed 2023-05-11 | $4.80M derived: sum of 3 quarters · filed 2023-05-11 | $2.43M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.66M derived: sum of 2 quarters · filed 2023-03-09 | -$711.00K derived: sum of 3 quarters · filed 2023-03-09 | -$4.83M 10-K · filed 2023-03-09 |
| 2021-09-30 | $515.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.86M derived: sum of 2 quarters · filed 2022-11-14 | -$5.98M 10-Q · filed 2022-11-14 | -$1.46M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$6.50M 10-Q · filed 2022-08-10 | -$1.98M derived: sum of 3 quarters · filed 2022-08-10 | -$2.95M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$4.12M 10-Q · filed 2022-05-16 | $393.00K derived: sum of 2 quarters · filed 2022-05-16 | -$583.00K derived: sum of 3 quarters · filed 2022-05-16 | $1.29M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.54M derived: sum of 2 quarters · filed 2022-03-17 | $5.41M derived: sum of 3 quarters · filed 2022-03-17 | $5.58M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$976.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $894.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.06M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $2.04M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $170.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |